Literature DB >> 15194513

The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential.

Kouji Kuno1, Kenji Bannai, Michinori Hakozaki, Kouji Matsushima, Kunitaka Hirose.   

Abstract

ADAMTS-1 is an ECM-anchored metalloproteinase with proteoglycan-degrading activity as well as an angiogenesis inhibiting activity. Here, we examined the effects of ADAMTS-1 overexpression on in vivo tumor growth and tumor metastasis. Overexpression of only the C-terminal half region of ADAMTS-1, consisting of TSP type I motifs and the spacer region, suppressed Chinese hamster ovary (CHO) tumor growth in mice. In addition, a significant reduction in tumor metastatic potential was observed in ADAMTS-1-transfected CHO cells in an experimental metastasis assay. Furthermore, deletional analyses revealed that the C-terminal half region of ADAMTS-1 is responsible for its experimental metastasis-inhibitory activity. Our data suggest that the C-terminal half region of ADAMTS-1 has therapeutic potential as an inhibitor of tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194513     DOI: 10.1016/j.bbrc.2004.05.105

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis.

Authors:  Masanari Obika; Hiroko Ogawa; Katsuyuki Takahashi; Jiayi Li; Omer Faruk Hatipoglu; Mehmet Zeynel Cilek; Toru Miyoshi; Junko Inagaki; Takashi Ohtsuki; Shozo Kusachi; Yoshifumi Ninomiya; Satoshi Hirohata
Journal:  Cancer Sci       Date:  2012-08-29       Impact factor: 6.716

2.  The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.

Authors:  Carmela Ricciardelli; Kate M Frewin; Izza de Arao Tan; Elizabeth D Williams; Kenneth Opeskin; Melanie A Pritchard; Wendy V Ingman; Darryl L Russell
Journal:  Am J Pathol       Date:  2011-10-12       Impact factor: 4.307

3.  Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively.

Authors:  Y-J Liu; Y Xu; Q Yu
Journal:  Oncogene       Date:  2006-04-20       Impact factor: 9.867

4.  ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein.

Authors:  Chuan-ju Liu; Wei Kong; Ke Xu; Yi Luan; Kiril Ilalov; Bantoo Sehgal; Shuang Yu; Ronald D Howell; Paul E Di Cesare
Journal:  J Biol Chem       Date:  2006-04-12       Impact factor: 5.157

Review 5.  The roles of ADAMTS in angiogenesis and cancer.

Authors:  Yi Sun; Jintuan Huang; Zuli Yang
Journal:  Tumour Biol       Date:  2015-04-28

6.  ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.

Authors:  Heléne Gustavsson; Tajana Tesan; Karin Jennbacken; Kouji Kuno; Jan-Erik Damber; Karin Welén
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

7.  Expression of ADAMTS1 and its correlation with angiogenesis in primary gastric cancer and lymph node metastasis.

Authors:  Jing Chen; Yu Zhi; Xiaojing Chang; Shuanglong Zhang; Dongqiu Dai
Journal:  Dig Dis Sci       Date:  2012-09-22       Impact factor: 3.199

8.  The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration.

Authors:  Cary Esselens; Jordi Malapeira; Núria Colomé; Carmen Casal; Juan Carlos Rodríguez-Manzaneque; Francesc Canals; Joaquín Arribas
Journal:  J Biol Chem       Date:  2009-11-13       Impact factor: 5.157

9.  Metalloprotease ADAMTS-1 decreases cell migration and invasion modulating the spatiotemporal dynamics of Cdc42 activity.

Authors:  Maíra de Assis Lima; Suély Vieira da Silva; Orlando Serrano-Garrido; Maren Hülsemann; Luana Santos-Neres; Juan Carlos Rodríguez-Manzaneque; Louis Hodgson; Vanessa M Freitas
Journal:  Cell Signal       Date:  2020-11-06       Impact factor: 4.315

10.  hHSS1: a novel secreted factor and suppressor of glioma growth located at chromosome 19q13.33.

Authors:  Katiana S Junes-Gill; Timothy K Gallaher; Zoya Gluzman-Poltorak; Joseph D Miller; Christopher J Wheeler; Xuemo Fan; Lena A Basile
Journal:  J Neurooncol       Date:  2010-07-31       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.